Synuca Therapeutics ApS: Financial statements 2025
CVR: 45367282
Source: annual report 2025, Danish Business Authority
30/01/2025 – 31/12/2025
Synuca Therapeutics ApS (CVR 45367282) has filed annual accounts for 2025. In 2025, the company reported a gross profit of EUR -256,439 and a net result of EUR -272,818. Equity in the 2025 report amounted to EUR -267,462. The company had 1 employee in the financial year.
- Gross Profit
- EUR -256,439
- Profit/Loss
- EUR -272,818
- Equity
- EUR -267,462
- Total Assets
- EUR 344,687
- Employees
- 1
Official annual report
How creditworthy is Synuca Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of January 30, 2025, EY Godkendt Revisionspartnerselskab has been appointed auditor of Synuca Therapeutics ApS.
As of January 30, 2025, William Brown is registered as director of Synuca Therapeutics ApS.
As of January 30, 2025, Lasse Reimer is registered as director of Synuca Therapeutics ApS.
As of January 30, 2025, CLAUS OLESEN HOLDING ApS is registered as an owner of Synuca Therapeutics ApS with an ownership share of 25%.
As of January 30, 2025, BODD ApS is registered as an owner of Synuca Therapeutics ApS with an ownership share of 25%.
Synuca Therapeutics ApS was founded on January 30, 2025.
About Synuca Therapeutics ApS
Synuca Therapeutics ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2025. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Lasse Reimer and William Brown. The board consists of Anker Gunvald Lundemose (chair), Claus Elsborg Olesen and Lasse Reimer. The company's owners include CLAUS OLESEN HOLDING ApS, BODD ApS and PHJ 2025 Holding ApS. According to the 2025 annual report, the company had an average of 1 employee. In 2025, the company reported a gross profit of EUR -256,439 and a net result of EUR -272,818. Equity in the 2025 report amounted to EUR -267,462.